Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

The injectable drug Ozempic is shown Saturday ... 503A and 503B, based on the FDA regulations that govern their operations. The latter is impacted by the ruling, according to industry experts.

Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

Since Ozempic hit the ... against our biology”. The FDA, his prior workplace, sets guidelines around food safety, he points out. But, he asks, why there are no regulations protecting the ...

That means they can make a version of semaglutide that is not identical or nearly identical to Ozempic and Wegovy ... and follow applicable FDA rules and regulations on compounding." ...